A comprehensive review of treatments for postmenopausal osteoporosis

Osteoporosis International

Volumn 14, Issue 1, 2003, Pages 2-12

  Hauselmann H J ^a   Rizzoli, R ^b  

^a KLINIK IM PARK   (Switzerland)

^b Faculty of Medicine   (Switzerland)

Author keywords

Bone; Bone mineral density; Fracture; Prevention

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; CALCITONIN; CALCITRIOL; CALCIUM ANTAGONIST; ETIDRONIC ACID; FLUORIDE; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

BONE DENSITY; BONE MASS; BONE MINERAL; CLINICAL TRIAL; EUROPE; FEMUR NECK; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; LUMBAR SPINE; NORTH AMERICA; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; VERTEBRA FRACTURE;

AGED; BONE DENSITY; FEMALE; HIP FRACTURES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS; SPINAL FRACTURES;

EID: 0037288822     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00198-002-1301-3     Document Type: Review

References (60)

1. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D (1997) Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporosis Int 7: 390-406
2. Schurch MA, Rizzoli R, Mermillod B et al. (1996) A prospective study on socioeconomic aspects of fracture of the proximal femur. J Bone Miner Res 11: 1935-1942
3. Cooper C, Campion G, Melton LJ (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2: 285-289
4. Guyatt GH (1998) Evidence-based management of patients with osteoporosis. J Clin Densitom 1: 395-402
5. Blank RD, Bockman RS (1999) A review of clinical trials of therapies for osteoporosis using fracture as an end point. J Clin Densitom 2: 435-452
6. Rosen CJ, Bilezikian JP (2001) Clinical review 123: Anabolic therapy for osteoporosis. J Clin Endocrinol Metab 86: 957-964
7. Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52: 377-384
8. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748
9. Windeler J, Lange S (1995) Events per person year - a dubious concept. BMJ 310: 454-456
10. 3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 327: 1637-1642
11. Ooms ME, Roos JC, Bezemer PD et al. (1995) Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial. J Clin Endocrinol Metab 80: 1052-1058
12. Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM (1996) Vitamin D supplementation and fracture incidence in elderly persons: a randomized, placebo-controlled clinical trial. Ann Intern Med 124: 400-406
13. Aloia JF, Vaswani A, Yeh JK et al. (1988) Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med 84: 401-408
14. McClung MR, Geusens P, Miller PD et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344: 333-340
15. Black DM, Cummings SR, Karpf DB et al. (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348: 1535-1541
16. Kleerekoper M, Peterson EL, Nelson DA et al. (1991) A randomized trial of sodium fluoride as a treatment for post-menopausal osteoporosis. Osteoporos Int 1: 155-161
17. Bone HG, Downs RW, Tucci JR et al. (1997) Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. J Clin Endocrinol Metab 82: 265-274
18. Chevalley T, Rizzoli R, Nydegger V et al. (1994) Effects of calcium supplements on femoral bone mineral density and vertebral fracture rate in vitamin-D-replete elderly patients. Osteoporos Int 4: 245-252
19. Reginster JY, Meurmans L, Zegels B et al. (1998) The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial. Ann Intern Med 129: 1-8
20. Ettinger B, Black DM, Mitlak BH et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282: 637-645
21. Cummings SR, Black DM, Thompson DE et al. (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280: 2077-2082
22. Pak CY, Sakhaee K, Adams-Huet B et al. (1995) Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med 123: 401-408
23. Harris ST, Watts NB, Genant HK et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282: 1344-1352
24. Reginster J, Minne HW, Sorensen OH et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11: 83-91
25. Liberman UA, Weiss SR, Broll J et al. (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333: 1437-1443
26. Recker RR, Hinders S, Davies KM et al. (1996) Correcting calcium nutritional deficiency prevents spine fractures in elderly women. J Bone Miner Res 11: 1961-1966
27. Chesnut CH, Silverman S, Andriano K et al. (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 109: 267-276
28. Ammann P, Rizzoli R, Meyer JM, Bonjour JP (1996) Bone density and shape as determinants of bone strength in IGF-I and/or pamidronate-treated ovariectomized rats. Osteoporos Int 6: 219-227
29. Turner CH, Burr DB (1993) Basic biomechanical measurements of bone: a tutorial. Bone 14: 595-608
30. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312: 1254-1259
31. Kanis JA, Gluer CC (2000) An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 11: 192-202
32. Hochberg MC, Ross PD, Black D et al. (1999) Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42: 1246-1254
33. Riggs BL, Hodgson SF, O'Fallon WM et al. (1990) Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322: 802-809
34. Meunier PJ, Delmas PD, Eastell R et al. (1999) Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. Clin Ther 21: 1025-1244
35. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15: 721-739
36. Neer RM, Arnaud CD, Zanchetta JR et al. (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434-1441
37. Meunier PJ, Slosman DO, Delmas PD et al. (2002) Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87: 2060-2066
38. Adami S, Passeri M, Ortolani S et al. (1995) Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 17: 383-390
39. Chesnut CH, McClung MR, Ensrud KE et al. (1995) Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 99: 144-152
40. Devogelaer JP, Broll H, Correa-Rotter R et al. (1996) Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 18: 141-150
41. Tucci JR, Tonino RP, Emkey RD et al. (1996) Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101: 488-501
42. Pols HA, Felsenberg D, Hanley DA et al. (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9: 461-468
43. 3, on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 54: 370-376
44. 3 on bone mineral density and incidence of fracture: a placebo-controlled, double-blind prospective study. Endocr J 43: 211-220
45. Overgaard K, Riis BJ, Christiansen C, Podenphant J, Johansen JS (1989) Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol (Oxf) 30: 435-442
46. Overgaard K, Hansen MA, Jensen SB, Christiansen C (1992) Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 305: 556-561
47. Thamsborg G, Jensen JE, Kollerup G et al. (1996) Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis. Bone 18: 207-212
48. Flicker L, Hopper JL, Larkins RG et al. (1997) Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis. Osteoporos Int 7: 29-35
49. Falch JA, Odegaard OR, Finnanger AM, Matheson I (1987) Postmenopausal osteoporosis: no effect of three years treatment with 1,25-dihydroxycholecalciferol. Acta Med Scand 221: 199-204
50. Gallagher JC, Goldgar D (1990) Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med 113: 649-655
51. Ott SM, Chesnut CH (1989) Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med 110: 267-274
52. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE (1997) Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337: 670-676
53. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322: 1265-1271
54. Harris ST, Watts NB, Jackson RD et al. (1993) Four-year study of intermittent cyclic etidronate treatment of post-menopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 95: 557-567
55. Meunier PJ, Sebert JL, Reginster JY et al. (1998) Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVO Study. Osteoporos Int 8: 4-12
56. Steiniche T, Hasling C, Charles P et al. (1989) A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. Bone 10: 313-320
57. Christiansen C, Riis BJ (1990) Five years with continuous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins, and bleeding pattern. Br J Obstet Gynaecol 97: 1087-1092
58. Lufkin EG (1992) Therapeutic alternatives for postmenopausal osteoporosis. Compr Ther 18: 14-17
59. Gonnelli S, Cepollaro C, Pondrelli C et al. (1997) The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis. J Bone Miner Res 12: 624-631
60. Recker RR, Davies KM, Dowd RM, Heaney RP (1999) The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial. Ann Intern Med 130: 897-904